In order for immune cells to effectively kill cancer cells, a triad of three cells are necessary — a dendritic cell, a cytotoxic “killer” T cell, and a helper T cell, researchers at MSK and Baylor College of Medicine have found. The discovery could alter the way doctors administer immunotherapies.
Researchers at Memorial Sloan Kettering Cancer Center (MSK) have discovered a new mechanism of resistance to KRAS inhibitors that suggests an opportunity to make the treatment more effective.
The University of New Mexico Comprehensive Cancer Cancer Center achieves accreditation for radiation oncology services from the American Society for Radiation Oncology APEx - Accreditation Program for Excellence
RWJBarnabas Health, the largest, most comprehensive academic health care system in New Jersey, along with Rutgers Cancer Institute, the state’s only National Cancer Institute-designated Comprehensive Cancer Center, have named Gerardo Capo, MD, as the Medical Director of Trinitas Comprehensive Cancer Center at Trinitas Regional Medical Center, an RWJBarnabas Health facility.
Recent advances in medical technology now allow experts to treat benign thyroid nodules using a minimally invasive, non-surgical treatment known as thyroid radiofrequency ablation (RFA). Dr. Toni Beninato, MD, MS, FACS, an endocrine surgeon in the Endocrine and Neuroendocrine Tumor Program at Rutgers Cancer Institute and RWJBarnabas Health shares more.
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Below are summaries of recent Fred Hutch Cancer Center research findings, patient stories and other news.
Sarcomas are a rare and diverse group of cancers that arise in the bones and soft tissues, often referred to as 'the forgotten cancer.' Rutgers Cancer Institute and RWJBarnabas Health expert Dr. Adam Berger shares more information on the disease during sarcoma awareness month.
"North American Cancer Center Clinical Research Capacity and Benchmarking in the Post-Pandemic Era" was published July 1 in JCO Oncology Practice, an American Society of Clinical Oncology (ASCO) Journal.
Moffitt Cancer Center researchers have developed a groundbreaking method for the scalable synthesis of withanolides.
Fred Hutch Cancer Center has launched (PS2@FH), a new summer research program that trains middle school and high school teachers in Fred Hutch labs to expand hands-on learning experiences they can take back to the classroom.
• 97% of HER2+, early-stage patients treated with trastuzumab emtansine (T-DM1) were free of cancer recurrence five years after treatment • Prognostic test (HER2DX) shown helpful in identifying patients at greatest risk for recurrence
Results from a new study led by researchers at The University of Texas MD Anderson Cancer Center support standard use of the more precise intensity-modulated radiotherapy (IMRT) over the alternative 3D-conformal radiotherapy (3D-CRT) for patients with unresectable, locally advanced non-small cell lung cancer (NSCLC).
MD Anderson and Rice announced the creation of the Cancer Bioengineering Collaborative to develop innovative technologies and bioengineering approaches to improve cancer research, diagnosis and treatment.
A new study led by researchers at Moffitt Cancer Center introduces an adaptive therapy approach that could optimize PARP inhibitor maintenance therapy, offering a more personalized and potentially less toxic treatment option for patients. Their work is featured as the cover article of the June 19 issue of Cell Systems.
NCCN shares new data on continued high prevalence for cancer drug shortages in the United States. In the latest survey, carboplatin and cisplatin shortages fell to 11% and 7% respectively, but 89% of centers surveyed continue to report shortages for at least one type of systemic therapy; 75% are experiencing two or more drug shortages.
These clinical trial results point to the first safe and effective use of immunotherapy for patients with microsatellite stable colorectal cancer, the most common subtype of the disease. The encouraging results of this phase I trial have prompted Dana-Farber investigators to move forward with a phase III trial of this immunotherapy combination.
In Greek mythology, a Chimera is a creature of change, a being possessing the forms of lion, goat and dragon. But unlike the mythical creature, a new approach to fighting cancer cells throughout the body is very real and has arrived at The University of New Mexico Comprehensive Cancer Center.
The FDA has expanded orphan drug designation for SurVaxM, a brain cancer immunotherapy born in the labs of Roswell Park Comprehensive Cancer Center. The supplemental designation applies to SurVaxM as treatment for not just adult glioblastoma but any malignant glioma in children or adults.
Research by Hemn Mohammadpour, DVM, PhD, and colleagues at Roswell Park Comprehensive Cancer Center offers new insights into tumor biology and may lay the groundwork for more effective cancer immunotherapy. Their preclinical findings were published today in the journal Cellular & Molecular Immunology.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right